• Global drug spending to hit $1.4 trillion in 2020: IMS

    Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will


  • Lessons from Australia and China’s Healthcare Cooperation: What Can Canadian Firms Learn?

    NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit


  • South Korea's Genexine expands into China in Tasgen deal for up to $100M

    South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i


Investment Opportunities

Opportunities

Potash in another mining friendly region other than Saskatchewan

With the junior mining sector struggling in the past few years, it is difficult for inv... Full Story

The hidden gems in CSE

Breaking News

Cardinal Health Plans $1.5 Billion Sale of China Drug Distribution Business

Cardinal Health, the second largest drug distributor in the US, is reported to be actively seeking a buyer for its China drug operations, with bids expected between $1.2 billion and $...

Huayi Joins $17M Round In Chinese Surgical Navigation Device Firm Symbow Medical

iKang Forms $74 Million Partnership for New China Healthcare Clinics

Shanghai-Israel Fund Co-Leads $9 Million Funding of Rapid Medical

New industrial wave will boost economy

Select Companies

Diamedica Inc

Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...

Resverlogix Corp

Resverlogix Corp is a clinical stage cardiovascular company. It is engaged in developing small mo...

Naturally Splendid Enterprises Ltd

Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commerc...

Experts Column

Top 10 Developments that Investors should pay extra attention in the new year

Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...

China could boost growth with supply, property reforms, tax cuts, HSBC says

China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...

Here’s how to play Chinese stocks in 2016?

Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...

G-20 sticks to 2% growth goal despite headwinds

The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...

Why isn't the yuan rising despite IMF support?

The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...

Press Release

VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

, announced it will host a conference call tomorrow, July 20 at 8:30 AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great...

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

, a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (&qu...

Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

, a wholly-owned subsidiary of VolitionRx Limited (Volition; NYSE MKT: VNRX), has signed an agreement to participate in a large multi-center clinical study with the Great Lakes New Englan...

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

Naturally Splendid Enterprises to Acquire 100% of Privately Owned Innovative Natural Food Company - Video News Alert on Investmentpitch.com

Preferred Dental Technologies Announces Initial Product Order and Engages Consultant for ISO Upgrade - Video News Alert on InvestmentPitch.com

Naturally Splendid Enters into Letter of Intent to Acquire Innovative Natural Food Company and Announces Private Placement Financing

Preferred Dental Implant Corp. Announces Initial Product Order

Top Hits News

Daily Top Performing Life Science Stocks
         Company Name Symbol Price Change Vol(k) Day's Range Contact
1 AEterna Zentaris Inc NASDAQ:AEZS 2.800
0.460 (19.66%)
47060373 2.55 - 3.29
2 ImmunoCellular Therapeutics Ltd NYSE MKT:IMUC 0.386
0.032 (8.99%)
3617304 0.3300 - 0.3900
3 Northwest Biotherapeutics Inc NASDAQ:NWBO 0.260
0.020 (8.29%)
1779845 0.2400 - 0.2700
4 OncoGenex Pharmaceuticals Inc NASDAQ:OGXI 0.460
0.030 (7.85%)
321927 0.44 - 0.48
5 VolitionRX Ltd NYSE MKT:VNRX 3.370
0.210 (6.65%)
34834 3.24 - 3.41
6 Alphatec Holdings Inc NASDAQ:ATEC 1.790
0.100 (6.14%)
50832 1.70 - 1.84
7 Esperion Therapeutics Inc NASDAQ:ESPR 48.800
2.600 (5.63%)
778281 46.10 - 50.05
8 OvaScience Inc NASDAQ:OVAS 1.550
0.080 (5.44%)
505621 1.47 - 1.60
9 Immunovaccine Inc TSX:IMV 1.210
0.060 (5.22%)
46431 1.18 - 1.23
10 TG Therapeutics Inc NASDAQ:TGTX 11.700
0.500 (4.46%)
1278264 11.10 - 11.85
11 EnteroMedics Inc NASDAQ:ETRM 4.550
0.180 (4.12%)
151062 4.44 - 4.68
12 Catalyst Pharmaceuticals Inc NASDAQ:CPRX 3.050
0.120 (4.10%)
1197905 2.89 - 3.08
13 Alimera Sciences Inc NASDAQ:ALIM 1.580
0.060 (3.95%)
1355431 1.51 - 1.65
14 Tenax Therapeutics Inc NASDAQ:TENX 0.740
0.030 (3.74%)
389833 0.69 - 0.77
15 Lifevantage Corp NASDAQ:LFVN 4.260
0.150 (3.65%)
75615 4.08 - 4.33
More